menu
    • menu

    Company profile for NodThera

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Smithfield BioScience transforms bioproducts into trusted, life-saving therapies through safe, reliable U.S.-based manufacturing.

    Virtual Booth

    Contact Supplier

    Quotient Sciences- Molecule to Cure. Fast.

    Virtual Booth

    Contact Supplier

    SWATI - Transforming science into solutions with 60+ years of expertise, global accreditations, and pioneering biotech innovation.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    NodThera is developing a new class of potent and highly selective NLRP3 inflammasome inhibitors for the treatment of diseases driven by chronic inflammation. We’re building a dynamic team of people across our offices in Cambridge, UK; Seattle, WA; and Lexington, MA; all united by our shared ambition, enthusiasm and creativity.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    NodTheraunitedkingdom_new Flag
    Country
    Country
    United Kingdom
    Address
    Address
    Suite 8, The Mansion Chesterford Research Park Little Chesterford CB10 1XL
    Telephone
    Telephone
    (617) 866-7350
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.nodthera.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/nodthera-limited/
    youtube
    YouTube
    Twitter
    Twitter
    https://x.com/NodThera

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Tides Asia

    Tides Asia

    Not Confirmed

    envelop Contact Supplier

    Tides Asia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    NodThera's NLRP3 inhibitor shows obesity promise in early trial
    NodThera's NLRP3 inhibitor shows obesity promise in early trial

    12 Jun 2024

    // James Waldron FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/nodtheras-nlrp3-inhibitor-shows-further-obesity-promise-phase-1b2a-trial

    James Waldron FIERCE BIOTECH
    12 Jun 2024
    Share Share
    NodThera touts potential weight loss effect of NLRP3 inhibitors
    NodThera touts potential weight loss effect of NLRP3 inhibitors

    20 Feb 2024

    // ENDPTS

    https://endpts.com/nodthera-touts-potential-weight-loss-effect-of-nlrp3-inhibitors/

    ENDPTS
    20 Feb 2024
    Share Share
    NodThera Announces Positive Phase 1 Study Readouts for the NLRP3
    NodThera Announces Positive Phase 1 Study Readouts for the NLRP3

    21 Sep 2022

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/nodthera-announces-positive-phase-1-study-readouts-for-the-nlrp3-inflammasome-inhibitors-nt-0796-and-nt-0249-301629146.html

    PRNEWSWIRE
    21 Sep 2022
    Share Share
    NodThera Announces Progress of NT-0796, a Novel NLRP3 Inflammasome
    NodThera Announces Progress of NT-0796, a Novel NLRP3 Inflammasome

    04 Nov 2021

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/nodthera-announces-progress-of-nt-0796-a-novel-nlrp3-inflammasome-inhibitor-into-a-phase-1-first-in-human-study-301415820.html

    PRNEWSWIRE
    04 Nov 2021
    Share Share
    Roche doubles down on promising inflammation field with Inflazome buy
    Roche doubles down on promising inflammation field with Inflazome buy

    25 Sep 2020

    // D.W. House SEEKING ALPHA

    https://seekingalpha.com/news/3616633-roche-doubles-down-on-promising-inflammation-field-inflazome-buy

    D.W. House SEEKING ALPHA
    25 Sep 2020
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search